LCZ696 Catalog No.:M8445-2 Smiles: CC(C)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F

Smiles: CC(C)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F

InChiKey: WSEKTEUGRLFBSE-UHFFFAOYSA-N

Chemical Name: methyl (3S)-3-[(2S)-2-[(2S)-2-{[(benzyloxy)carbonyl]amino}-3-methylbutanamido]propanamido]-5-fluoro-4-oxopentanoate

Derazantinib inhibits FGFR1-4 but no other receptor tyrosine kinases in cell-free kinase assay

LCZ696 Catalog No.:M8445-2 Smiles: CC(C)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)FLCZ696 is a potent ARNi inhibitor and an investigational drug to treat heart failure. Chemically, LCZ696 is a mixture of valsartan and sacubitril in a 1: 1 molar ratio. As of 2014 it is being developed by Novartis. LCZ696 is co crystallized valsartan and sacubitril, in a one to one molar ratio. According to Sci Finder database, LCZ696 has a formula as (valsartan)(sacubitril)(3Sodium)(5 2 hydrate), or (2 valsartan)(2 sacubitril) (6 Sodium)(5 hydrate),